.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its own top biopharma pick for 2025 and rated another 9 names in the room as overweight. The investment financial institution claimed in a keep in mind that it remains to believe “diabesity is actually set to end up being.